Demonstration of blood flow patterns in human soft tissue sarcomas using 99mTc-labelled hexamethyl propyleneamineoxime

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium

OBJECTIVE

To define the efficacy of thalidomide on the overall survival of patients with metastatic recurrent gynecologic sarcomas.

PATIENTS AND METHODS

All patients with sarcoma or carcinosarcoma of gynecologic origin and documented recurrence or persistence of disease after appropriate surgery, radiation therapy and/or chemotherapy were recruited to the study. All patients were ambulatory and had measurable disease that could be documented on CT scan. Patients were started on 200 mg/day of thalidomide orally every night and escalated by 100-200 mg every 7 to 14 days. The length of the treatment was separated into 2 cycles with the first 84 days defined as the first cycle and the next 56 days as the second cycle. Common Toxicity Criteria were used to record toxicities. Because thalidomide was postulated to induce cytostasis, the end-points were progression-free and overall survival in this mixed group of patients.

RESULTS

Seventeen patients were enrolled. The drug was not well tolerated because of constipation, fatigue, worsening performance status, drowsiness and sleepiness. The total dosage of medication given to each patient ranged from 3200 mg to 40,500 mg. The maximum dosage reached in each patient ranged from 300 mg to 750 mg, with the total time of treatment ranging from 13 to 99 days. All patients had progression of disease with a median progression-free survival time of 1.84 months (CI 1.54-2.79 months) and a median overall survival of 6.64 months.

DISCUSSION

Thalidomide has no activity in patients with advanced or recurrent gynecologic sarcomas and was not well-tolerated. The overall survival was <7 months. The progression-free survival was <3 months, and, since the therapy was not tolerated well, we unanimously decided to close the study at this point. Despite the poor result, we still believe in the strategy of anti-angiogenesis and will continue to pursue other potential treatment options using the same concept.

Blood flow measurement in extremity soft tissue sarcoma with technetium-99m hexamethyl-propyleneamineoxime and single photon emission computed tomography

Blood flow measurements were made in 28 patients with soft tissue sarcoma of the extremities to investigate the prognostic significance of tumour vascularity. Four patients with benign tumours also underwent blood flow measurement. Mean and maximum tumour blood flow was calculated from technetium-99m hexamethyl-propyleneamineoxime uptake measured using single photon emission computed tomography (SPECT), tumour volume measured from SPECT transaxial image reconstructions and cardiac output assessed with Doppler ultrasonography. Twenty-seven malignant lesions and one benign tumour showed increased uptake of isotope relative to surrounding tissues. Mean sarcoma blood flow varied between 1 and 33 ml per 100 ml tumour per min, and maximum flow between 5 and 57 ml per 100 ml per min. Fourteen patients developed progressive disease during the first year of follow-up. Eight of 11 patients with a high isotope uptake ratio, eight of 12 with a high mean blood flow and eight of 14 with a high maximum blood flow relative to the respective medians for the series showed disease progression.

Radiation effects on uptake of 99Tcm-hexamethylpropylen amine oxime (HMPAO) in head and neck tumours

Twenty patients with malignant head and neck tumours were imaged with 99Tcm-labelled hexamethylpropylene amine oxime (HMPAO), a radiopharmaceutical generally used for blood flow studies. Before radiotherapy (RT), 93% of the tumours could be detected with single photon emission computed tomography (SPECT) and 45% with planar imaging. Whole tumour-to-background 99TcmHMPAO uptake ratios ranged from 3.6 to 1.0 (mean 1.7 +/- 0.6) in untreated tumours. There was a good correlation between tumour volume and uptake (r = 0.69, P = 0.002). Sixteen patients were reimaged during or shortly after radical RT. 99TcmHMPAO uptake was significantly lower after treatment (mean uptake ratio 1.2 +/- 0.3, P less than 0.001). However, RT associated changes in 99TcmHMPAO uptake were in agreement with the clinical response in only 63% of the studies. This study indicates that 99TcmHMPAO SPECT imaging can be used for pretherapeutic localisation of head and neck tumours. Although most tumours show a decrease in uptake after irradiation the poor association with tumour regression does not allow for reliable assessment of treatment response.

The effects of single dose oral hydralazine on blood flow through human lung tumours

Hydralazine has been shown to reduce tumour blood flow and to potentiate the cytotoxicity of melphalan and bioreductive agents in mice. In order to determine whether such a strategy might have clinical potential, a study was undertaken to investigate the effects of hydralazine on blood flow through human tumours. Twenty-two patients with carcinoma of the bronchus received a single oral dose of hydralazine in the range 25 to 150 mg (0.37-2.86 mg/kg) according to age and acetylator status. Tumour blood flow was assessed by single photon emission computed tomography (SPECT) performed 10 min following intravenous 99Tcm-HMPAO on two occasions 2-8 days apart, the second being performed 60 min after hydralazine administration. In 20 evaluable patients, hydralazine caused a 38% increase in blood flow through the whole tumour (p = 0.007) and a 28% increase in flow through the tumour centre (p = 0.03) with greater increases occurring in patients sustaining greater falls in peripheral resistance. Tumour vascular resistance fell indicating active vasodilation in arterioles supplying tumours. Side-effects due to hydralazine were reported by eight patients.